MedTrace Logo

Single Dose Study Of PF-04171327 And Prednisone On Carbohydrate Metabolism

NCT01199900 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2010-12-17

No results posted yet for this study

Summary

This study will investigate the effect of a single dose of PF-04171327 or prednisone on calculated measures of glucose tolerance and insulin resistance by using a modified oral glucose tolerance test

Conditions

  • Healthy

Interventions

DRUG

PF-04171327

25 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test (OGTT)

DRUG

PF-04171327

25 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test (OGTT)

DRUG

Prednisone

5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)

DRUG

PF-04171327

3 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)

DRUG

PF-04171327

10 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)

DRUG

Prednisone

5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)

DRUG

Prednisone

5 mg tablets predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01199900 on ClinicalTrials.gov